Key result
Novel surgical strategies offer treatment options for heart failure patients ineligible for traditional surgery.
Why the study?
Traditional surgical approaches for ischemic cardiomyopathy cannot be offered to a large group of patients, necessitating new strategies.
Newer generation ventricular assist devices, passive ventricular restraint devices, and cellular-based therapies have the potential to expand surgical treatment options for patients with ischemic cardiomyopathy who are not candidates for traditional operations.
Ischemic cardiomyopathy affects an estimated 3 million people in the USA and is the most common cause of heart failure. Traditional operations have included heart transplantation, myocardial revascularization, mitral valve repair, left ventricular reconstruction, first-generation left ventricular assist devices and cardiac resynchronization therapy. These operations have become safer in recent times, due to improved technologies. Current technologies and surgical approaches can benefit a significant number of patients. However, there remains a large group of patients in whom traditional approaches can not be offered. Newer generation ventricular assist devices, passive ventricular restraint devices and cellular-based therapies (including skeletal- and bone marrow-derived stem cells) have the potential to be more universal in their applications. Ongoing investigations with each of these modalities will allow surgeons to offer treatment to patients who are not considered surgical candidates at this time.
No takes yet. Share an insight, caveat, or question.
Ailawadi et al. (2008) conducted a review in Ischemic cardiomyopathy. Newer generation ventricular assist devices, passive ventricular restraint devices and cellular-based therapies vs. Traditional operations was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: